Loughborough University The Centre for Biological Engineering Doc Ref: FS008.1 : HTA-PR-FORM/007 Acquisition and Receipt of Biological Materials Issue Date:

ARF No: CBE/ARF/000 15

PART A: To be completed by the	Receiver (a separate	form must be	completed for	each sample	type)		
A1. Details of Sample/Specimen							
Type/ID: (eg primary cell, cell line, tissu fluid, excreta, biological agent)	<i>e, body</i> Haematopoi	Haematopoietic Cell based Therapies				⊠Human □Animal	
Format / Quantity: (eg vials, slides, e	3x50mL tube	e containing 20r	mL ficol unit	3 39		g.	
Tissue site/Organ source:		od				□N/A	
Batch N°:				•			
Is the sample/specimen consider If No, go to section A2.		⊠Yes □No					
Is the material obtained from an	use?	⊠Yes □No					
Is the material obtained for storage and use under a project specific NHS REC approval?						□Yes □No	
Is the material licensable under the HTA? Indicate source below:						⊠Yes □No	
☑HTA licensed organisation ☑C				land, Wales o	or N.Ireland)		
identifier) & the corresponding (74053282)		. 65 x 3 510201701-03		Assigned Unique ID (Procuro): S00077437			
If Yes, provide Project Ref N°:	RA010						
If Yes, provide the name of the P	Dr Rob Thon	Dr Rob Thomas					
A2. Details of Receipt							
Date/Time of receipt Date		05/10/2017		Time:	*		
ID of Receiver	Name:	Jon Harriman		Dept:	CBE		
ID of Supplier/Provider	Name:	Anthony Nolan		Country:	UK		
PART B: To be completed by the	Receiver						
B1. Inspection and Quarantine							
Has a biological risk assessment for the use of this material been approved?		⊠Yes □No	Ref Number: BRA060 & BRA010				
Physical integrity of the material(s) acceptable?		⊠Yes □No	If No, describe action taken				
Quantity received correct?		⊠Yes □No	If No, describe action taken				
Labelling correct and legible?		⊠Yes □No	If No, describe action taken				
If No, add reference or details to ensure traceability	C of A or equivalent quality	evidence of	⊠Yes □No □N/A				
	Agreements to enal		⊠Yes □No □N/A				
	Details/evidence/assurance of consent		⊠Yes □No □N/A				

	Other (describe) □Yes □No □N/A			
Temporary storage - Quarantine location (as applicable)	Building/Room	CBE H19 Cold store & once 80 overnight and transferr		e processed will be stored in - ed to Liquid N2 - Bank 7	
	Storage Unit ID				
	Within storage	in storage unit location ID Bank7 Rack2 Box0			3.
	Date/Time of q	COMPOSITIVE STORES OF DESCRIPTION OF STREET			
Submitted by:	Signature:		Date:		
	Kalin &	\sim	7/10/2017		
PART C: To be completed by th	ne departmental Q	uality Manager			
C1. Quality Assurance Checks					
Has the sample/specimen beer	□Yes □No □N/A	5			
Has the donor been screened for	√Yes □No □N/A				
Has the sample/specimen beer	□Yes □No □N/A				
Is there evidence that the supp or other recognised certificatio	□Yes □No □N/A				
For HTA licensable material, is to and use of the material under t	□Yes □No □N/A				
Is there sufficient evidence to s	□Yes □No □N/A				
C2. Approval for release from	quarantine			/	
Can the material be released fr released for processing?	om quarantine and	transferred to desi	gnated storage area or	☑Yes □No	
If No, provide recommendations for deposition of the material and the results of any action relating to non-conforming material.		☐ Accept as is, but with extra controls			
		☐ Rework or reprocess to meet the specified requirements		`	
		☐Test to meet specified requirements		· · · · · · · · · · · · · · · · · · ·	
		☐Return to supplier/provider			
		□Disposal		,	
		Building/Room		CRE	
		Storage Unit ID			
If Yes, provide details of storage applicable)	e location (as	Within storage unit location ID		Bank 7 rack 2 Boke	13
		Database Refere	nce	·	
		Date/Time of transfer			
Approved by:		Signature:		Date:	
			,	11/10/17	